Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction

SIMPLE SUMMARY: The prognosis of high-risk neuroblastoma improved significantly with the addition of an anti-GD2 monoclonal antibody (dinutuximab) administered in the post-Consolidation setting. A subsequent study demonstrated improved efficacy when administering chemotherapy with dinutuximab to pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cupit-Link, Margaret, Federico, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527563/
https://www.ncbi.nlm.nih.gov/pubmed/37760578
http://dx.doi.org/10.3390/cancers15184609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527563/
https://www.ncbi.nlm.nih.gov/pubmed/37760578
http://dx.doi.org/10.3390/cancers15184609

Ejemplares similares